Victoria Johnson

Panelists reached broad consensus that upfront dual oral combination therapy with an ERA and PDE5 inhibitor remains the foundational standard.

FDA cited manufacturing and labeling issues in its CRL for cytisinicline, with no clinical efficacy or safety deficiencies reported.

HCPLive convened an in-depth roundtable discussion on advancing biologic therapy for asthma and COPD in a complex real-world prescribing environment.

An expert clinical forum explores recent updates in the field and incorporating sotatercept treatment.

Explore APAPP’s Las Vegas meeting with hands-on POCUS and airway labs, COPD and ILD bootcamps, AI updates, and new therapy insights.

LATITUDE Atlas saw more than 35% of patients receiving zasocitinib 30 mg once daily reaching a PASI100 response at week 16, the primary endpoint.

An APP forum discusses navigating a complex biologic landscape with significant administrative, access, and patient education responsibilities that physicians may encounter less directly.

May 2026 spotlights the ATS 2026 conference and the ALA's State of the Air report.

A clinical forum discussed referral dynamics, access barriers, and patient health literacy challenges that shape biologic use in the real world.

Experts unpack new asthma/COPD biologics, eosinophil+FeNO targeting, twice-yearly depemokimab switching, and payer hurdles in 2026 care.

New OX40 biologics aim for longer atopic dermatitis control, but Kaposi's sarcoma concerns split experts as amlitelimab advances and rocatinlimab halts.

The FDA has approved budesonide/glycopyrrolate/formoterol fumarate as the first single-inhaler triple therapy for asthma.

FDA approved lunsotogene parvec for OTOF-related hearing loss based on phase 1/2 data showing improved hearing in a small cohort.

FDA approved dupilumab for children aged 2 to 11 years with chronic spontaneous urticaria uncontrolled by H1 antihistamines.

Phase 3 MIRANDA found tozorakimab reduced COPD exacerbations in former smokers despite inhaled maintenance therapy.

Experts unpack new T2-targeted biologics for severe asthma and eosinophilic COPD, sharing biomarker tips, sequencing debates and payer hurdles,

Sanofi’s dual TSLP/IL‑13 bispecific cuts asthma exacerbations and shrinks nasal polyps, while atopic dermatitis results disappoint.

The Q1 recap for pulmonology spotlights regulatory and clinical advances across asthma and pulmonary fibrosis.

March 2026 saw new data from pivotal clinical trials and new expert conversations on HCPLive.

Check out 6 FDA decisions to watch in Q2 2026, listed chronologically by expected decision date.

Read 6 updates from the meeting that clinicians managing atopic dermatitis should know.

Check out exclusive expert interviews of late breaking data from AAD 2026.

Results from the phase 3 trial were published in NEJM and simultaneously presented as a late-breaking abstract at AAD 2026.

The IMMpactful direct comparison provides prospective data in a moderate psoriasis population that previous MAICs could not fully capture.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Tildrakizumab is US FDA-approved for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Phase 3b ENCORE shows inhaled ARIKAYCE boosts culture conversion and symptoms in antibiotic‑naïve MAC lung disease, paving way for 2026 label expansion.

Clinicians compare newest asthma/COPD biologics, highlighting dupilumab’s edge, biomarker shifts, and insurance barriers shaping real-world use.

Allergy experts weigh ruxolitinib, tapinarof, and roflumilast—new nonsteroidal creams that reshape atopic dermatitis care beyond steroids.